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Prognostic value of prostate 
volume in non‑muscle invasive 
bladder cancer
Won Sik Ham1, Jee Soo Park1,2, Won Sik Jang1, Young Deuk Choi1 & Jongchan Kim1,3*
There is evidence that a history of benign prostatic hyperplasia increases the incidence of bladder 
cancer, and treatment with 5‑alpha reductase inhibitor or androgen deprivation therapy reduces 
recurrence of non‑muscle invasive bladder cancer. We aimed to evaluate whether prostate volume 
affects its prognosis. We reviewed medical records of men who underwent transurethral resection 
of bladder tumor due to non‑muscle invasive bladder cancer from January 2012 to December 
2017. Patients were divided into two groups based on prostate volume measured by computed 
tomography (group 1: 264 patients with ≤ 30 mL, group 2: 124 patients with > 30 mL). Propensity score 
matching analysis was used for adjust selection bias, and then assessed recurrence‑free survival and 
progression‑free survival. With a median follow up duration of 52 months, group 1 showed higher 
5‑year recurrence‑free and progression‑free survival (69.3% vs 47.0%, p = 0.001; 96.7% vs 87.7%, 
p = 0.002). Further, cox‑regression analysis showed that tumor size (HR = 1.292 p < 0.001), multifocal 
tumor (HR = 1.993, p < 0.001), adjuvant intravesical therapy (chemotherapy: HR = 0.580, p = 0.037 
and bacillus Calmette–Guérin: HR = 0.542, p = 0.004) and prostate volume (HR = 2.326, p < 0.001) 
were significant predictors of recurrence‑free survival. Prostate volume (HR = 2.886, p = 0.014) was 
also associated with PFS with age (HR = 1.043, p = 0.044) and tumor grade (HR = 3.822, p = 0.013). We 
conclude higher prostate volume is associated with worse recurrence and progression‑free survival in 
non‑muscle invasive bladder cancer.
Bladder cancer is the ninth most common cancer in the world and fourth most common cancer in  men1. Approx-
imately 70–75% of bladder cancer cases are classified as non-muscle invasive bladder cancer (NMIBC) at the 
time of  diagnosis2. Among the patients with NMIBC, 40–80% patients experience recurrence and approximately 
15–40% experience progression after transurethral resection of bladder tumor (TURBT). Prior recurrence is 
known to be one of the risk factors for progression of NMIBC and once it has progressed, the prognosis tends 
to be  poor3,4. Although radical cystectomy is needed in patients with T2 or higher grades of the disease, it is 
related with decrease in quality of  life5. Hence, it is important to predict recurrence and progression of NMIBC 
to counsel patients.
The reported prognostic factors of NMIBC are old age, female sex, smoking history, presence of carcinoma 
in situ (CIS), tumor size, tumor multifocality, tumor stage, and tumor grade. The European Organization for 
Research and Treatment of  Cancer3,4 and Spanish Club for Oncological  Treatment6 group have devised progres-
sion models using some of these factors. In addition to the demographic and pathologic characteristics, intravesi-
cal therapy using bacillus Calmette–Guérin (BCG) or mitomycin-C have been found to help reduce recurrence 
and progression in a few patients with  NMIBC7,8.
In addition, there have been several studies that have found other factors that are associated with the prog-
nosis of NMIBC. Some studies have reported that presence of benign prostatic hyperplasia (BPH) is associated 
with increased incidence of bladder  cancer9,10. Other studies have shown that using 5-alpha reductase inhibitors 
(5-ARI) in BPH or androgen deprivation therapy (ADT) in prostate cancer also reduces recurrence of bladder 
 cancer11,12. BPH is treated with as it reduces prostate volume (PV)13. 5-ARI and ADT are inhibiting androgen 
receptor (AR) signaling and also known to be related to PV  reduction14. And some studies reported AR plays 
roles in the development of  BPH15. Based on these studies PV might be the indicator reflect AR and we aimed 
to assess if PV as an indicator associated with AR is a potential prognostic factor for NMIBC.
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Results
Patients characteristics. Table 1 shows the patients’ clinical and pathologic characteristics of all cohort 
and propensity score matched cohort. The median age (69.0 vs 62.0 years, p < 0.001) and body mass index (BMI) 
(24.3 vs 23.7, p = 0.011) were higher in group 2 than in group 1. Tumor size was also greater in group 2 (1.8 cm 
vs 1.5 cm, p = 0.0.39). Additionally, high-grade tumors (60.2% vs 46.8%) and T1 stage tumors (92.6% vs 83.9%) 
were more frequently observed in group 2 than in group 1. There was no difference in the other variables. After 
propensity score matching (PSM), there was no difference in all variables between two groups.
Recurrence‑free and prognosis‑free survival in the 2 groups (before PSM). In the median fol-
low up duration of 52 months (interquartile range: 38–72 months), 66 patients (26.6%) experienced recurrence 
in group 1 and 53 patients (49.1%) in group 2, while 8 patients (3.2%) experienced progression in group 1 and 
14 patients (13.0%) in group 2. Figure 1 showed Kaplan–Meier curves of recurrence-free survival (RFS) and 
progression-free survival (PFS) in two groups. The 5-year RFS was higher in group 1 than in group 2 (69.3% vs 
47.0%, p = 0.001), and so was the PFS (96.7% vs 87.7%, p = 0.002).
Multivariable cox-regression analysis showed that tumor size (hazard ratio [HR] = 1.286, 95% confidential 
interval [CI] = 1.119–1.477, p < 0.001) and multifocal tumor occurrence (HR = 1.838, 95% CI = 1.251–2.700, 
p = 0.002) were associated with RFS. Adjuvant intravesical BCG instillation was associated with better RFS 
(HR = 0.605, 95% CI = 0.394–0.929, p = 0.022), although intravesical chemotherapy did not lower RFS (HR = 0.634, 
95% CI = 0.372–1.081, p = 0.094). High grade of tumor (HR = 4.411, 95% CI = 14.379–14.11, p = 0.012) was asso-
ciated with worse PFS, and high PV was a significant bad prognostic factor for both RFS (HR = 2.176, 95% 
CI = 1.508–3.141, p < 0.001) and PFS (HR = 3.213, 95% CI = 1.325–7.791, p = 0.010) (Table 2).
Recurrence‑free and prognosis‑free survival in the 2 groups (after PSM). Figure  2 showed 
Kaplan–Meier curves of RFS and PFS in matched cohort. The 5-year RFS was higher in group 1 than in group 2 
(66.2% vs 47.9%, p = 0.003), and so was the PFS (96.9% vs 86.9%, p = 0.009).
Table 3 demonstrated multivariable cox-regression analysis after PSM and it showed similar results of pre-
matched analysis. Tumor size (HR = 1.243, 95% CI = 1.050–1.470, p = 0.011) and multifocal tumor occurrence 
(HR = 1.787, 95% CI = 1.128–2.832, p = 0.013) were associated with RFS. Adjuvant intravesical BCG instilla-
tion was also associated with better RFS (HR = 0.575, 95% CI = 0.345–0.959, p = 0.034). High grade of tumor 
(HR = 5.939, 95% CI = 1.080–16.18, p = 0.040) was associated with worse PFS. High PV was a significant 
bad prognostic factor for both RFS (HR = 2.060, 95% CI = 1.324–3.206, p = 0.001) and PFS (HR = 4.855, 95% 
CI = 1.391–16.94, p = 0.013).
Table 1.  Patients characteristics of group 1 (prostate volume ≤ 30 mL) and group 2 (prostate volume > 30 mL). 
IQR interquartile range, BMI body mass index, CIS carcinoma in situ, BCG bacillus Calmette–Guérin.
Characteristics
Pre-propensity score matching Post- propensity score matching
Group 1 Group 2
p-value
Group 1 Group 2
p-value248 108 107 107
Age (median, IQR) 62.0 (53.5–71.0) 69.0 (62.0–76.0) < 0.001 65.0 (57.0–74.0) 68.0 (62.0–76.0) 0.128
BMI (median, IQR) 23.7 (21.7–25.8) 24.3 (22.4–26.6) 0.011 24.2 (21.9–26.2) 24.2 (22.4–26.4) 0.242
Smoking 0.270 0.550
Non-smoker 64 (25.8%) 34 (31.5%) 30 (28.0%) 34 (31.8%)
Current or former smoker 184 (74.2%) 74 (68.5%) 77 (72.0%) 73 (68.2%)
Tumor size (median, IQR) 1.5 (1.0–2.3) 1.8 (1.0–2.8) 0.039 1.6 (1.1–2.5) 1.8 (1.0–2.8) 0.736
Multifocal tumor 119 (48.0%) 52 (48.1%) 0.977 55 (51.4%) 52 (48.1%) 0.682
Tumor grade 0.020 0.020
Low grade 132 (53.2%) 43 (39.8%) 51 (47.7%) 43 (40.2%)
High grade 116 (46.8%) 65 (60.2%) 56 (52.3%) 64 (59.8%)
Pathologic T stage 0.027 0.122
pTa 40 (16.1%) 8 (7.4%) 15 (14.0%) 8 (7.5%)
pT1 208 (83.9%) 100 (92.6%) 92 (86.0%) 99 (92.5%)
Tumor variant 14 (5.6%) 10 (9.3%) 0.211 9 (8.4%) 10 (9.3%) 0.810
CIS 10 (4.0%) 4 (3.7%) 0.883 3 (2.8%) 4 (3.7%) > 0.999
Immediate intravesical therapy 26 (10.5%) 9 (8.3%) 0.531 8 (7.5%) 9 (8.4%) 0.800
Adjuvant intravesical therapy 0.201 0.537
No 138 (55.6%) 49 (45.4%) 55 (51.4%) 48 (44.9%)
Chemotherapy 36 (14.5%) 20 (18.5%) 37 (34.6%) 39 (36.4%)
BCG 74 (29.8%) 39 (36.1%) 15 (14.0%) 20 (18.7%)
3
Vol.:(0123456789)
Scientific Reports |        (2021) 11:18784  | https://doi.org/10.1038/s41598-021-98045-1
www.nature.com/scientificreports/
Discussion
There are various prognostic factors of NMIBC such as old age, female sex, presence of CIS, tumor size, tumor 
multifocality, tumor stage, and tumor grade. Some studies have shown that BPH is associated with an increased 
risk of bladder cancer; an epidemiological case–control study reported that previous prostatic surgery due to 
BPH was associated with increased risk of bladder cancer (relative risk = 2.38)9. A recent study reported that 
moderate to severe lower urinary tract symptoms (LUTSs) were associated with poor prognosis of  NMIBC16. It 
has also been reported that the International Prostate Symptom Score was a significant predictor of recurrence of 
NMIBC (odds ratio = 1.26, p = 0.005). LUTSs are commonly associated with bladder outlet obstruction (BOO), 
which is often caused by benign prostatic  enlargement17. Therefore, it is possible that the high PV is also related 
to the prognosis; hence, this study focused on PV.
Figure 1.  Kaplan–Meier curves for recurrence-free survival (a) and progression-free survival (b) in group 1 
(prostate volume ≤ 30 mL) and group 2 (prostate volume > 30 mL) before propensity score matching.
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We reviewed another study that gave a glimpse of the possible link between prostate and bladder cancer. 
Izumi et al. reported that the 5-year RFS was higher in the ADT group than in the control group (76% vs 40%, 
p < 0.001). They also showed that ADT was an independent prognostic factor for bladder cancer recurrence 
(HR = 0.29, p < 0.001)12. Other studies have reported that androgen suppression therapies such as 5-ARI and 
ADT reduce the risk of intravesical recurrence of bladder cancer (HR = 0.36, p = 0.024)11. The authors explain 
that the results of these studies could be related to androgen receptors (ARs). In fact, many studies have reported 
that AR signaling in bladder cancer cases was associated with recurrence and progression of bladder  cancer18,19. 
Wang et al. also reported that 5-ARI might lower mortality related with bladder  cancer20. Based on these results, 
we concur that recurrence of bladder cancer is more likely to be due to AR signaling. And previous studies have 
reported that AR plays an important role in enhancing cell growth in both stromal and epithelial cells, and it 
promotes development of  BPH15,21. Referring to those studies, the size of the prostate may also have some influ-
ence on the prognosis of bladder cancer.
Although there are many modalities to measure PV, transrectal ultrasonography (TRUS) with the elliptical 
volume formula is most frequently used. However, we measured the PV using preoperative computed tomog-
raphy (CT) performed for staging because TRUS was not available to all patients who had undergone TURBT. 
TRUS has clear advantages, including less radiation, ready availability, and cost-effectiveness22. On the other 
hand, it has the significant disadvantage of intra-operator variability. Zlotta et al.23 reported that the variability in 
the PV measurement ranges from -21% to 30%. Although some previous studies had reported PV was measured 
to be larger in CT than TRUS, more recent studies showed no  differences24. We also found no significant dif-
ference in PV between TRUS and CT (28.8 mL vs 28.3 mL, p = 0.260) in 77 patients who received TRUS before 
surgery in our study.
Our study showed that high PV was associated with both recurrence and progression. RFS and PFS were 
higher in group 1 than in group 2. Multivariable cox analysis showed that a greater PV was associated with worse 
RFS and PFS. The hypothesis for the cause of these results is that, as mentioned above, the prognosis of bladder 
cancer is related to AR signaling. AR is likely to be relatively suppressed in people with small prostates, thereby 
suppressing the recurrence and progression of bladder cancer. Another possible explanation for the results is 
the effect of residual urine. 5-ARI reduces PV by the activity of androgen-regulated growth factor, which is ulti-
mately responsible for angiogenesis. In fact, a previous study showed that the expression of VEGF was reduced 
in the prostate of patients with huge prostate using 5-ARI25. And decreased PV with using 5-ARI contributes to 
reducing residual  urine26. In addition, a previous animal study, Kadlubar et al. reported that as the frequency 
of urination increased, the level of carcinogen in the urothelium  decreased27. Another study showed that the 
higher the fluid intake, the lower the risk of bladder  cancer28. These studies suggest that the risk and recurrence 
of bladder cancer increase with higher carcinogen exposure.
Table 2.  Multivariable analyses of factors associated with recurrence-free survival and progression-free 
survival with all cohort. HR hazard ratio, BMI body mass index, CIS carcinoma in situ, BCG bacillus Calmette–
Guérin.
Variables
Recurrence-free survival Progression-free survival
HR (95% CI) p-value HR (95% CI) p-value
Age 1.008 (0.993–1.023) 0.280 1.040 (0.998–1.085) 0.064
BMI 0.986 (0.924–1.054) 0.686 0.987 (0.839–1.162)
Smoking 0.515 0.257
Non-smoker 1 (Ref.) 1 (Ref.)
Current or former smoker 1.151 (0.753–1.760) 0.582 (0.229–1.482)
Tumor size 1.286 (1.119–1.477) < 0.001 0.891 (0.613–1.294) 0.544
Multifocal tumor 1.838 (1.251–2.700) 0.002 1.726 (0.648–4.600) 0.275
Tumor grade 0.585 0.012
Low grade 1 (Ref.) 1 (Ref.)
High grade 0.889 (0.582–1.357) 4.411 (1.379–14.11)
Pathologic T stage 0.071 0.555
pTa 1 (Ref.) 1 (Ref.)
pT1 2.041 (0.940–4.429) 1.938 (0.216–17.41)
CIS 2.362 (0.960–6.227) 0.082 1.828 (0.314–10.63) 0.502
Immediate intravesical therapy 0.811 (0.431–1.529) 0.518 0.756 (0.157–3.649) 0.728
Adjuvant intravesical therapy
No 1 (Ref.) 1 (Ref.)
Chemotherapy 0.634 (0.372–1.081) 0.094 0.152 (0.019–1.225) 0.077
BCG 0.605 (0.394–0.929) 0.022 0.845 (0.338–2.115) 0.720
Prostate volume < 0.001 0.010
≤ 30 mL 1 (Ref.) 1 (Ref.)
> 30 mL 2.176 (1.508–3.141) 3.213 (1.325–7.791)
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In addition to the pathological characteristics of bladder cancer, there have been various studies on factors 
affecting the prognosis of bladder cancer. Regarding various chronic diseases, Ferro et al.29 reported that type 2 
diabetes mellitus increased the risk of recurrence and progression of high-grade MIBC. Regarding hematological 
characteristics, there was a study that reported baseline basophil might be predictor of BCG-treated high-grade 
 NMIBC30. In addition, there have been studies that circulating tumor cells are also an important prognostic 
factor for bladder  cancer31,32. For the prediction of recurrence and progression of NMIBC, the development of 
a predictive model that includes various factors including prostate size will help in counseling patients, making 
treatment decisions and making follow-up decisions.
Our study has some limitations. Although we established the relationship between PV and prognosis of 
NMIBC, the mechanism is still unknown. We believe that AR and residual urine play an important role. In order 
Figure 2.  Kaplan–Meier curves for recurrence-free survival (a) and progression-free survival (b) in group 1 
(prostate volume ≤ 30 mL) and group 2 (prostate volume > 30 mL) after propensity score matching.
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to confirm this in more depth, it would be helpful to assess the relationship between residual urine and the prog-
nosis of NMIBC, including female population. Moreover, we have not been able to determine how therapeutic 
measures and transurethral resection of the prostate (TURP) for prostatic hyperplasia affect the prognosis of 
bladder cancer. Ham et al.33 reported that simultaneous TURP with TURBT reduces recurrence rate in men with 
BOO. They reported concomitant TURP was a significant factor in predicting recurrence of NMIBC without 
increased risk of recurrences in the bladder neck or prostatic urethra. However, subsequent studies did not 
increase the risk of recurrence of the bladder neck or prostatic urethra, but reported that it did not significantly 
affect the recurrence of the bladder. Randomized control study demonstrated concurrent TURP was associated 
with better RFS, although it was not statistically significant (HR = 0.294, p = 0.083)34. A study on how treatment 
of large PV affects the recurrence of bladder cancer in appropriate patient groups will help to better understand 
the relationship between prostate size and the prognosis of bladder cancer.
Another drawback is that our results might be sensitive to selection bias because this study was retrospective 
and non-randomized in nature. The number of patients included in this study was also relatively small, and the 
follow-up duration could have been longer. These could reason out why prognostic factors previously known 
to affect prognosis were found not to be associated. Only PV and tumor grade were especially associated with 
progression of NMIBC.
Despite of those drawbacks, our study showed that PV is an independent prognostic factor of NMIBC. High 
PV was found to be associated with worse RFS and PFS. Our study suggested that PV reduction could be helpful 
for prevention of recurrence and progression in patients with NMIBC.
Methods
Patient selection. We reviewed the medical records of 735 men who underwent TURBT due to NMIBC 
without regional lymph node or distant metastasis between January 2012 and December 2017 at Severance Hos-
pital, Seoul, Korea. The exclusion criteria were as follows: (1) patients who had undergone previous TURBT; (2) 
patients who had undergone surgery for upper urinary tract urothelial carcinoma; (3) patients who had under-
gone previous or concurrent prostatic surgery, such as TURP or prostatectomy; (4) patients who were prescribed 
with 5-ARI; (5) patients with incomplete resection of tumor or second-look TURBT; and (6) patients with miss-
ing data and short follow-up duration. Finally, 356 patients were included in this study (Fig. 3).
Patient characteristics. We investigated the following data in all patients: age, BMI, tumor size and mul-
tifocality, tumor grade, pathologic tumor stage, presence of CIS, intravesical therapy and PV. PV was assessed 
using a CT scan, which was performed for the purpose of staging before TURBT, and was calculated using the 
Table 3.  Multivariable analyses of factors associated with recurrence-free survival and progression-free 
survival with propensity score matched cohort. HR hazard ratio, BMI body mass index, CIS carcinoma in situ, 
BCG bacillus Calmette–Guérin.
Variables
Recurrence-free survival Progression-free survival
HR (95% CI) p-value HR (95% CI) p-value
Age 1.005 (0.987–1.024) 0.555 1.012 (0.961–1.066) 0.641
BMI 0.986 (0.910–1.067) 0.724 0.981 (0.815–1.180) 0.835
Smoking 0.490 0.144
Non-smoker 1 (Ref.) 1 (Ref.)
Current or former smoker 1.194 (0.721–1.978) 0.447 (0.152–1.317)
Tumor size 1.243 (1.050–1.470) 0.011 0.864 (0.552–1.351) 0.521
Multifocal tumor 1.787 (1.128–2.832) 0.013 1.741 (0.527–5.755) 0.363
Tumor grade 0.292 0.040
Low grade 1 (Ref.) 1 (Ref.)
High grade 0.760 (0.456–1.266) 5.939 (1.080–16.18)
Pathologic T stage 0.359 0.729
pTa 1 (Ref.) 1 (Ref.)
pT1 1.515 (0.623–3.683) 0.667 (0.068–6.574)
CIS 2.030 (0.522–7.894) 0.307 1.601 (0.257–9.965) 0.614
Immediate intravesical therapy 0.519 (0.202–1.337) 0.174 1.348 (0.231–7.869) 0.74
Adjuvant intravesical therapy
No 1 (Ref.) 1 (Ref.)
Chemotherapy 0.624 (0.335–1.163) 0.138 0.191 (0.022–1.626) 0.130
BCG 0.575 (0.345–0.959) 0.034 1.158 )0.400–3.354) 0.787
Prostate volume 0.001 0.013
≤ 30 mL 1 (Ref.) 1 (Ref.)
> 30 mL 2.060 (1.324/3.206) 4.855 (1.391–16.94)
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ellipsoid formula referring to a previous study: 0.52 × [width (cm)] × [length (cm)] × [height (cm)]24. The assess-
ment was performed twice by two urologists, and the average value was determined.
Patients were divided into two groups based on their calculated PV: group 1 included 248 patients with 
PV ≤ 30 mL, and group 2 included 108 patients with PV > 30 mL. These two groups were compared for the 
previously mentioned variables to evaluate whether there was a statistically significant difference between them.
Follow‑up. The follow-up schedule including intravesical BCG therapy or chemotherapy, which decided by 
the attending physician based on the classification of cancer risk. Cystoscopy with urine cytology was performed 
every 3 months for the first year, every 6 months for the second year, and every 6–12 months thereafter. Evalu-
ation for upper urinary tract or distant metastasis was performed every 6–12 months, as needed. Tumor recur-
rence was defined with confirmation on histopathological examination when it was suspected on cystoscopy. 
Tumor progression was defined as a diagnosis of muscle invasive bladder cancer, or regional node or distant 
metastasis.
Statistical analyses. Patient characteristics were compared between the two groups using the Mann–
Whitney U test for continuous data and Chi-squared test for dichotomous variables. Categorical variables are 
presented as frequencies and percentages, whereas continuous variables are expressed as medians and interquar-
tile ranges. Then propensity score matching was performed using five factors which showed statically difference 
between two groups: age, BMI, tumor size, tumor grade and pathologic T stage (Caliper: 0.01). With propensity-
score matched cohort, Kaplan–Meier curves and the log-rank test were used to depict and compare RFS and 
PFS between the two groups. Multivariable Cox regression models were constructed to determine the variables 
associated with RFS and PFS. All tests were two-sided, with statistical significance considered at p < 0.05. The 
statistical analyses were performed using STATA ® version 15.1 (StataCorp LLC, College Station, TX, USA).
Good clinical practice protocols. The study protocol was approved by the institutional review board of 
the Yongin Severance Hospital. (Approval number: 9-2020-0173) And this study was performed in agreement 
with the applicable laws and regulations, good clinical practices, and ethical principles described in the Declara-
tion of Helsinki s and written informed consent was obtained from all patients.
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Figure 3.  Flowchart of patient selection.
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